Australia markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
18.22+0.02 (+0.14%)
As of 10:54AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close18.19
Open18.40
Bid18.19 x 800
Ask18.20 x 1200
Day's range18.18 - 18.39
52-week range12.43 - 20.93
Volume257,947
Avg. volume1,138,092
Market cap57.185B
Beta (5Y monthly)1.09
PE ratio (TTM)22.45
EPS (TTM)0.81
Earnings dateN/A
Forward dividend & yield0.84 (4.61%)
Ex-dividend date30 Mar 2020
1y target est23.60
  • Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
    Business Wire

    Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

    Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.

  • BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana
    Business Wire

    BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana

    BioLife Plasma Services announces opening of first plasma collection center in Louisiana.

  • Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study
    Motley Fool

    Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study

    The results provide more justification for the FDA to grant the substance emergency use authorization.